Literature DB >> 21041733

Blockade of programmed death-1 in young (New Zealand black x New Zealand white)F1 mice promotes the activity of suppressive CD8+ T cells that protect from lupus-like disease.

Maida Wong1, Antonio La Cava, Ram P Singh, Bevra H Hahn.   

Abstract

The programmed death-1 (PD-1)/programmed death-1 ligand 1 (PD-L1) pathway regulates both stimulatory and inhibitory signals. In some conditions, PD-1/PD-L1 inhibits T and B cell activation, induces anergy, and reduces cytotoxicity in CD8(+) T cells. In other conditions, PD-l/PD-L1 has costimulatory effects on T cells. We recently showed that induction of suppressive CD8(+)Foxp3(+) T cells by immune tolerance of lupus-prone (New Zealand black × New Zealand white)F(1) (BWF(1)) mice with the anti-DNA Ig-based peptide pConsensus (pCons) is associated with significantly reduced PD-1 expression on those cells. In this study, we tested directly the role of PD-1 by administering in vivo neutralizing Ab to PD-1 to premorbid BWF(1) and healthy control mice. Anti-PD-1-treated mice were protected from the onset of lupus nephritis for 10 wk, with significantly improved survival. Although the numbers of T cells declined in aging control mice, they were maintained in anti-PD-1-treated mice, including CD8(+)Foxp3(+) T cells that suppressed syngeneic CD4(+)CD25(-) T cell proliferation and IFN-γ production, reduced production of IgG and anti-dsDNA IgG, induced apoptosis in syngeneic B cells, and increased IL-2 and TGF-β production. The administration of anti-PD-1 Ab to BWF(1) mice after induction of tolerance with pCons abrogated tolerance; mice developed autoantibodies and nephritis at the same time as control mice, being unable to induce CD8(+)Foxp3(+) T suppressor cells. These data suggest that tightly regulated PD-1 expression is essential for the maintenance of immune tolerance mediated by those CD8(+)Foxp3(+) T cells that suppress both T(h) cells and pathogenic B cells. PD-1 regulation could represent a target to preserve tolerance and prevent autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21041733     DOI: 10.4049/jimmunol.0903401

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo.

Authors:  Janine Gotot; Catherine Gottschalk; Sonny Leopold; Percy A Knolle; Hideo Yagita; Christian Kurts; Isis Ludwig-Portugall
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-11       Impact factor: 11.205

2.  CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.

Authors:  Amy J Beres; Dipica Haribhai; Alexandra C Chadwick; Patrick J Gonyo; Calvin B Williams; William R Drobyski
Journal:  J Immunol       Date:  2012-05-30       Impact factor: 5.422

3.  Analysis of PD-1 and Tim-3 expression on CD4+ T cells of patients with rheumatoid arthritis; negative association with DAS28.

Authors:  Zohreh Koohini; Hadi Hossein-Nataj; Maryam Mobini; Aref Hosseinian-Amiri; Alireza Rafiei; Hossein Asgarian-Omran
Journal:  Clin Rheumatol       Date:  2018-04-07       Impact factor: 2.980

4.  Dependence of Glomerulonephritis Induction on Novel Intraglomerular Alternatively Activated Bone Marrow-Derived Macrophages and Mac-1 and PD-L1 in Lupus-Prone NZM2328 Mice.

Authors:  Sun-Sang J Sung; Yan Ge; Chao Dai; Hongyang Wang; Shu Man Fu; Rahul Sharma; Young S Hahn; Jing Yu; Thu H Le; Mark D Okusa; Warren K Bolton; Jessica R Lawler
Journal:  J Immunol       Date:  2017-02-20       Impact factor: 5.422

Review 5.  Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus.

Authors:  Vasileios C Kyttaris; George C Tsokos
Journal:  Curr Opin Rheumatol       Date:  2011-09       Impact factor: 5.006

Review 6.  Genes, tolerance and systemic autoimmunity.

Authors:  Ram P Singh; Richard T Waldron; Bevra H Hahn
Journal:  Autoimmun Rev       Date:  2011-11-30       Impact factor: 9.754

Review 7.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

Review 8.  Co-stimulatory and Co-inhibitory Pathways in Autoimmunity.

Authors:  Qianxia Zhang; Dario A A Vignali
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

9.  Blockade of programmed death-1 in young (New Zealand Black x New Zealand White)F1 mice promotes the suppressive capacity of CD4+ regulatory T cells protecting from lupus-like disease.

Authors:  Maida Wong; Antonio La Cava; Bevra H Hahn
Journal:  J Immunol       Date:  2013-05-01       Impact factor: 5.422

Review 10.  Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer.

Authors:  Pilar Martín; Rafael Blanco-Domínguez; Raquel Sánchez-Díaz
Journal:  Cell Mol Immunol       Date:  2020-11-24       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.